78 FR 229 pg. 70953 - Draft Guidance for Industry on Bioequivalence Recommendations for Fluticasone Propionate; Salmeterol Xinafoate; Reopening of the Comment Period
Type: NOTICEVolume: 78Number: 229Page: 70953
Page: 70953Docket number: [Docket No. FDA-2007-D-0369]
FR document: [FR Doc. 2013-28394 Filed 11-26-13; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Food and Drug Administration
Official PDF Version: PDF Version
[top]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2007-D-0369]
Draft Guidance for Industry on Bioequivalence Recommendations for Fluticasone Propionate; Salmeterol Xinafoate; Reopening of the Comment Period
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice; reopening of the comment period.
SUMMARY:
The Food and Drug Administration (FDA) is reopening the comment period for the notice of availability entitled "Draft Guidance for Industry on Bioequivalence Recommendations for Fluticasone Propionate; Salmeterol Xinafoate", published in the Federal Register of September 10, 2013 (78 FR 55263). In that notice, FDA requested public comment on the draft guidance. FDA is reopening the comment period due to the inability of some commenters to submit comments through the www.regulations.gov Web site from November 4, 2013, through November 13, 2013, due to technical difficulties.
DATES:
Submit either electronic or written comments to the docket by December 11, 2013.
ADDRESSES:
Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Bhawana Saluja, Center for Drug Evaluation and Research (HFD-643), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-8465.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of September 10, 2013 (78 FR 55263), FDA announced the notice of availability for the draft guidance entitled "Draft Guidance for Industry on Bioequivalence Recommendations for Fluticasone Propionate; Salmeterol Xinafoate." Interested persons were given until November 12, 2013, to provide comments. The Agency is reopening the comment period until December 11, 2013 to allow interested persons additional time to submit comments.
II. Request for Comments
Following publication of the September 10, 2013, notice of availability, there were technical difficulties with the www.regulations.gov Web site from November 4, 2013, through November 13, 2013, which would have prevented comments from being submitted.
III. How To Submit Comments
Interested persons may submit either electronic comments regarding this document to http://www.regulations.gov or written comments to the Division of Dockets Management (see ADDRESSES ). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at http://www.regulations.gov.
Dated: November 20, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-28394 Filed 11-26-13; 8:45 am]
BILLING CODE 4160-01-P